secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncternal Therapeutics, Inc. (—)
CIK:        0001260990
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0000950170-24-105987
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncternal cuts 37% workforce, discontinues two clinical trials, explores strategic alternatives
--------------------------------------------------------------------------------

- Workforce reduction of ~10 employees (37%) to preserve cash; severance charges of ~$1.0M expected in Q3 2024.
- CMO Salim Yazji to depart effective October 1, 2024, with severance benefits.
- Discontinues ONCT-534 (prostate cancer) after interim Phase 1 showed no clinically meaningful PSA improvement in 20 patients.
- Discontinues ONCT-808 (CAR T for B-cell lymphoma); had complete metabolic response but one death at highest dose.
- Company will cease all product development and pursue strategic alternatives including sale, merger, or asset licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/0000950170-24-105987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/onct-20240911.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-105987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer